JMP Securities Reaffirms Buy Rating for Blueprint Medicines (NASDAQ:BPMC)

Blueprint Medicines (NASDAQ:BPMC – Get Rating)‘s stock had its “buy” rating restated by research analysts at JMP Securities in a research report issued on Monday, TipRanks reports. They presently have a $152.00 price target on the biotechnology company’s stock. JMP Securities’ price objective points to a potential upside of 132.20% from the company’s previous close. […]

Related Keywords

United States ,Stifel Nicolaus ,Ariel Hurley ,Jeffreyw Albers ,Morgan Stanley ,Blueprint Medicines Corporation ,Securities Exchange Commission ,Zacks Investment Research ,Ensign Peak Advisors Inc ,Voya Investment Management ,Dimensional Fund Advisors ,Citigroup ,Blueprint Medicines ,Get Rating ,Investment Research ,Exchange Commission ,Technologies Capital Management ,Investment Management ,Peak Advisors Inc ,Fund Advisors ,Medicines Corporation ,Nasdaq Bpmc ,Bpmc ,Medical ,Reiterated Rating ,Jmp Securities ,